Inhaltsbereich
| 53 Einträge | 1, 2, 3 › » |
Seite 1 / 3
 Druckansicht
|
| Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. |
| Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF |
| Lancet (London, England). 2015 May 31. pii: S0140-6736(15)60995-3. doi: 10.1016/S0140-6736(15)60995-3 |
| PMID: 26040499 |
| Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. |
| Pluschnig U, Haslik W, Bayer G, Soleiman A, Bartsch R, Lamm W, Steger GG, Zielinski CC, Mader RM |
| Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2014 Nov 30. doi: 10.1007/s00520-014-2535-2 |
| PMID: 25433440 |
| Indocyanine green video angiography predicts outcome of extravasation injuries. |
| Haslik W, Pluschnig U, Steger GG, Zielinski CC, Schrögendorfer KF, Nedomansky J, Bartsch R, Mader RM |
| PloS one. 2014 Aug 21. doi: 10.1371/journal.pone.0103649. pii: PONE-D-14-14898. pmc: PMC4140719 |
| PMID: 25144707 |
| The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. |
| Kandioler D, Schoppmann SF, Zwrtek R, Kappel S, Wolf B, Mittlböck M, Kührer I, Hejna M, Pluschnig U, Ba-Ssalamah A, Wrba F, Zacherl J |
| The Journal of thoracic and cardiovascular surgery. 2014 Jul 22. pii: S0022-5223(14)00905-2. doi: 10.1016/j.jtcvs.2014.06.079 |
| PMID: 25135238 |
| Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. |
| Ilhan-Mutlu A, Preusser M, Schoppmann SF, Asari R, Ba-Ssalamah A, Schwameis K, Pluschnig U, Birner P, Püspök A, Zacherl J, Hejna M |
| Anticancer research. 2013 Jul 30. pii: 33/8/3455 |
| PMID: 23898119 |
| Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the "Breast Imaging Reporting and Data System" for multiparametric 3-T imaging of breast lesions. |
| Pinker K, Bickel H, Helbich TH, Gruber S, Dubsky P, Pluschnig U, Rudas M, Bago-Horvath Z, Weber M, Trattnig S, Bogner W |
| European radiology. 2013 Mar 16. doi: 10.1007/s00330-013-2771-8 |
| PMID: 23504036 |
| Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. |
| Pluschnig U, Schoppmann SF, Preusser M, Datler P, Asari R, Ba-Ssalamah A, Schwameis K, Birner P, Zacherl J, Hejna M |
| Anticancer research. 2013 Mar 13. pii: 33/3/1035 |
| PMID: 23482778 |
| Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer. |
| Arnold T, Michlmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, Bachleitner-Hofmann T, Oehler R |
| European journal of clinical investigation. 2013 Jan 25. doi: 10.1111/eci.12043 |
| PMID: 23410002 |
| Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer. |
| Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch R |
| The breast journal. 2013 Jan 27. doi: 10.1111/tbj.12070 |
| PMID: 23350584 |
| Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. |
| Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG |
| European journal of cancer (Oxford, England : 1990). 2012 Mar 27. pii: S0959-8049(12)00247-X. doi: 10.1016/j.ejca.2012.03.002 |
| PMID: 22459763 |
| Brain metastases free survival differs between breast cancer subtypes. |
| Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R |
| British journal of cancer. 2012 Jan 10. pii: bjc2011597. doi: 10.1038/bjc.2011.597. pmc: PMC3273356 |
| PMID: 22233926 |
| Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. |
| Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG |
| British journal of cancer. 2011 Nov 29. pii: bjc2011531. doi: 10.1038/bjc.2011.531. pmc: PMC3251869 |
| PMID: 22127284 |
| Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. |
| Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Oct 13. pii: 1078-0432.CCR-11-1846. doi: 10.1158/1078-0432.CCR-11-1846 |
| PMID: 21998336 |
| High resolution MRI of the breast at 3 T: which BI-RADS® descriptors are most strongly associated with the diagnosis of breast cancer? |
| Pinker-Domenig K, Bogner W, Gruber S, Bickel H, Duffy S, Schernthaner M, Dubsky P, Pluschnig U, Rudas M, Trattnig S, Helbich TH |
| European radiology. 2011 Sep 14. doi: 10.1007/s00330-011-2256-6 |
| PMID: 21913060 |
| A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. |
| Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Aug 1. pii: 1078-0432.CCR-11-0926. doi: 10.1158/1078-0432.CCR-11-0926 |
| PMID: 21807638 |
| Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna. |
| Bojic M, Pluschnig U, Zacherl J, Thallinger CM, Ba-Ssalamah A, Maresch J, Datler P, Schoppmann SF, Hejna M |
| Anticancer research. 2011 Jul 8. pii: 31/6/2379 |
| PMID: 21737668 |
| HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases. |
| Schoppmann SF, Jesch B, Zacherl J, Wrba F, Hejna M, Maresch J, Langer FB, Riegler MF, Pluschnig U, Birner P |
| The British journal of surgery. 2011 May 25. doi: 10.1002/bjs.7562 |
| PMID: 21618213 |
| Expression of Her-2 in carcinomas of the esophagus. |
| Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P |
| The American journal of surgical pathology. 2010 Nov 25. doi: 10.1097/PAS.0b013e3181f8be17. pii: 00000478-201012000-00016 |
| PMID: 21107094 |
| Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value. |
| Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R |
| British journal of cancer. 2010 Sep 28. pii: 6605909. doi: 10.1038/sj.bjc.6605909. pmc: PMC2967072 |
| PMID: 20877360 |
| Temporary placement of self-expanding oesophageal stents as bridging for neo-adjuvant therapy. |
| Langer FB, Schoppmann SF, Prager G, Tomaselli F, Pluschnig U, Hejna M, Schmid R, Zacherl J |
| Annals of surgical oncology. 2009 Oct 27. doi: 10.1245/s10434-009-0760-6 |
| PMID: 19859771 |
| 53 Einträge | 1, 2, 3 › » |
Seite 1 / 3
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
